REFRACTORY HODGKIN LYMPHOMA
Clinical trials for REFRACTORY HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo aims to outsmart Hard-to-Treat lymphomas
Disease control Recruiting nowThis early-phase study tests whether combining two drugs—nivolumab (an immunotherapy that helps the immune system attack cancer) and ASTX727 (a pill that makes chemotherapy more effective)—is safe and can shrink tumors in people with B-cell lymphoma that has returned or stopped r…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:19 UTC
-
New drug HCB301 takes on tough cancers in early human trial
Disease control Recruiting nowThis early-phase study tests an investigational drug called HCB301 in adults with advanced solid tumors or classical Hodgkin lymphoma that has come back or not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumo…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: FBD Biologics Limited • Aim: Disease control
Last updated May 26, 2026 04:11 UTC
-
Promising combo targets Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests a combination of two drugs—pembrolizumab and all-trans retinoic acid (ATRA)—in adults with relapsed or refractory Hodgkin lymphoma or B-Non-Hodgkin lymphoma. The goal is to see if the combo is safe and helps shrink tumors. About 24 participants will receive the t…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Rita Assi • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
Radioactive antibody cocktail aims to beat back stubborn hodgkin lymphoma
Disease control Recruiting nowThis study tests a new approach for Hodgkin lymphoma that has returned or not responded to treatment. It combines a radioactive antibody (yttrium-90 anti-CD25) with standard chemotherapy (BEAM) before a stem cell transplant. The goal is to kill cancer cells more effectively and i…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 18, 2026 12:02 UTC